Selank (10 mg Vial) Dosage Protocol
Selank is a synthetic heptapeptide derived from tuftsin, developed by Russian researchers as an anxiolytic and nootropic without sedation or dependence.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Selank 10 mg intranasal research calculations for 5 mL and 10 mL final volumes
Selank 10 mg Nasal Spray Dosage Calculations
Each option begins with 3.0 mL in the peptide vial. Transfer the complete solution, then add enough vehicle to reach the measured final volume.
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL actuation |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 2,000 mcg/mL | 200 mcg 50 nominal actuations |
| 10.0 mL | About 7.0 mL | 1,000 mcg/mL | 100 mcg 100 nominal actuations |
| 6.67 mL (registered-product concentration reference) | About 3.67 mL | 1,500 mcg/mL | 150 mcg 66.7 nominal actuations |
Published Intranasal Research Schedule
| Period | Amount | actuation Volume | Frequency |
|---|---|---|---|
| Days 1–14 | 300 mcg per administration (900 mcg/day) | 0.20 mL at 1.5 mg/mL (2 verified 0.10 mL actuations) | 3 times daily |
Research reference only: This translates the registered 0.15% Selank drop schedule into volume for a verified 0.10 mL actuator. A custom research solution and pump are not equivalent to the registered preserved formulation.
Calculation basis: Each row uses the full 10 mg vial and a pump verified to release 0.10 mL per complete actuation. Nominal actuation counts are calculated before priming and normal residual hold-up.
How to Prepare the 5 mL or 10 mL Research Bottle
- Confirm: Verify the 10 mg vial, compatible sterile research vehicle, actuator bottle capacity, and documented pump output.
- Dissolve: Add 3.0 mL of compatible sterile vehicle to the vial with aseptic transfer technique, then gently swirl until dissolved. Do not shake.
- Transfer and measure: Transfer the complete solution into the sterile actuator bottle and add enough vehicle to reach exactly 5.0 mL or 10.0 mL final volume.
- Label and prime: Secure the pump; label the peptide amount, final volume, concentration, pump output, and preparation date; then prime according to the actuator instructions and record the priming actuations.
Vehicle context: The worked example can use sterile 0.9% saline as a research vehicle. The registered 0.15% Selank product contains 1.5 mg/mL Selank in purified water with methylparaben, so the saline example is not the same as the manufactured multidose drop formulation.
Mathematical Actuator Equivalents
| Literature Amount | 5 mL Option 200 mcg each actuation | 10 mL Option 100 mcg each actuation |
|---|---|---|
| 300 mcg | 1.5 theoretical actuations | 3 actuations |
| 900 mcg | 4.5 theoretical actuations | 9 actuations |
| 2,700 mcg | 13.5 theoretical actuations | 27 actuations |
These rows are concentration conversions, not a universal schedule. Fractional results are mathematical only because a metered pump cannot deliver half of a full actuation. Amounts reported with a manufactured drop formulation should not be treated as direct generic-pump instructions.
Use the measured final volume and verified actuator output in every calculation. Bottle capacity alone does not establish the final volume or the amount delivered per actuation.
Intranasal (IN) Research Summary
Published Intranasal Selank Clinical Studies
Human Selank anxiolytic research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.
| Source | Research Context | Published Intranasal Amount and Formulation |
|---|---|---|
| Zozulia et al., 2008 [1] | 62 adults with GAD or neurasthenia | Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14. |
| Syunyakov et al., 2012 [2] | 20 adults with GAD | 2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure. |
| Panikratova et al., 2020 [4] | Healthy-volunteer functional connectivity study | One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount. |
The current manufacturer instruction describes a 0.15% nasal-drop product at 1.5 mg/mL, with two drops placed in each nasal passage three times daily for 14 days. Those drop counts belong to the registered bottle and finished formulation. They are not direct equivalents to a different metered pump.
Reference concentration: Mathematically, 10 mg brought to about 6.67 mL equals 1.5 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not a reproduction of the registered preserved drop product.
Nasal Spray Device Output & Conversion Math
Selank Nasal Spray Actuator Math
A 0.10 mL actuator is a common nasal pump configuration, but pump output is not universal. Pharmaceutical literature reports pump volumes from approximately 0.025 mL to 0.20 mL per actuation. Use the manufacturer specification or a validated measurement for the exact device.
Core Formula
mcg per actuation = (10,000 mcg / final volume in mL) x verified mL per actuation
nominal actuations = final volume in mL / verified mL per actuation
| Verified Actuator Output | 5 mL Option 2,000 mcg/mL | 10 mL Option 1,000 mcg/mL |
|---|---|---|
| 0.05 mL | 100 mcg | 50 mcg |
| 0.10 mL | 200 mcg | 100 mcg |
| 0.13 mL | 260 mcg | 130 mcg |
Actuator Checks Before Recording a Result
- Confirm the stated volume per full actuation for the specific pump.
- Follow the documented priming and repriming procedure.
- Record residual volume and tail-off near bottle exhaustion when estimating usable actuations.
- Keep pump orientation and actuation stroke consistent during the research procedure.
FDA nasal spray guidance treats pump delivery, priming, dose uniformity, and bottle exhaustion as product performance variables.
DCH HERO END
Supplies Needed
Supplies Needed
Use one complete set of measured and sterile research supplies for each prepared Selank 10 mg nasal bottle.
| Item | Quantity |
|---|---|
| Selank 10 mg research vial | One vial per prepared bottle, with lot-specific identity, purity, and assay documentation. The supplier card below links to the existing Selank 10 mg product page. [8] |
| Sterile research vehicle | Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle. |
| Sterile nasal actuator bottle | One 5 mL or 10 mL bottle intended for single-user research. |
| Metered pump | A compatible actuator documented or verified at 0.10 mL per complete actuation. |
| Calibrated transfer tools | Sterile syringes or pipettes that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume. |
| Sterile transfer needle | Required when the peptide vial uses a rubber septum. |
| Clean handling supplies | Alcohol preparation pads, clean gloves, and a disinfected work surface. |
| Label and research log | Record the peptide amount, final volume, concentration, pump output, preparation date, priming actuations, and actuation count. |
| Storage materials | Light-protective, temperature-controlled storage appropriate to the validated formulation. |
| Sharps container | Use when transfer needles are part of the preparation workflow. |
Protocol Overview
The peptide does not produce dependence or sedation, making it different from benzodiazepine-class anxiolytics. Intranasal route is the standard in Russian clinical practice. Effects on anxiety typically appear within the first week of dosing.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) modeled on the natural immunomodulatory peptide tuftsin. It modulates GABA, serotonin, and BDNF (brain-derived neurotrophic factor) systems, producing anxiolytic effects without sedation, dependence, or cognitive impairment.
Potential Benefits & Side Effects
Potential Benefits
- Anxiolytic effects without sedation or dependence.
- Nootropic / mild cognitive enhancement reported.
- Improved stress tolerance in animal models.
- Long Russian clinical literature in anxiety disorders.
Side Effect Profile
- Generally well-tolerated.
- Mild injection-site or nasal-irritation possible.
- Long-term human safety data outside Russian literature limited.
Lifestyle Factors
- Intranasal route is most common in Russian clinical practice.
- Cycled use (4-week on, 2-week off) is typical.
Injection Technique
- Intranasal spray (most common) or subcutaneous.
- Rotate injection sites if dosing sub-Q.